AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study: ThGRF peptide improves immune function among elderly.(Brief Article)
2002 JUL 10 - (NewsRx.com & NewsRx.net) -- Theratechnologies has announced the successful completion of a phase II clinical trial to determine the efficacy and safety profile of the ThGRF (TH9507) peptide on the immune response of elderly people to influenza vaccine.
This phase II trial was a proof-of-concept study to determine ThGRF's potential to improve the immune system of patients who experience immune dysfunctions.
The chosen model for this study was influenza vaccination in elderly patients, known to be prone to medical complications related to influenza, especially pneumonia, because of their impaired immune system. This model permitted rapid access to a homogeneous group of patients, all exposed to an identical immunological challenge with a vaccine.
"This trial has demonstrated emphatically ...
- Theratechnologies: 2002 Highlights and Year End Financial Results; - Major...
- Press release article from: PR Newswire February 25, 2003 700+ words
...based products. - Effect of ThGRF on immune functions: In...Theratechnologies demonstrated that ThGRF, through its ability to...impact on cell-mediated immune response and an excellent safety profile. - Effect of ThGRF in cognitive functions...
- Theratechnologies initiates Phase II clinical trial in Canada and the US for...
- Press release article from: PR Newswire May 22, 2003 700+ words
...patient in a new Phase II clinical study for ThGRF, its growth hormone-releasing factor...basis of the favorable clinical profile of ThGRF observed in previous studies as well as...Undertaking this trial fits with our ThGRF program strategy aimed at making ThGRF...
- Theratechnologies: US Phase II Clinical Study Confirms Safety of ThGRF in...
- Press release article from: PR Newswire January 29, 2003 700+ words
...Phase II study to evaluate the safety of ThGRF, its growth hormone releasing factor analogue...patients with type II diabetes shows that ThGRF is safe and well-tolerated and does not...this study, Theratechnologies can develop ThGRF in a broader clinical population, having...
- Theratechnologies: ThGRF a potential treatment for patients with wasting...
- Press release article from: PR Newswire October 21, 2003 700+ words
...preliminary results for a Phase II study testing ThGRF, its growth hormone-releasing factor...condition and provide a rationale for moving ThGRF into late-stage development in COPD wasting...promising, because they demonstrate that ThGRF has the potential to bring clinical benefit...
- Theratechnologies: patient enrolment completed in hip fracture Phase II...
- Press release article from: PR Newswire July 9, 2003 700+ words
...to evaluate the efficacy and safety of ThGRF, a growth hormone-releasing factor analogue...at evaluating the efficacy and safety of ThGRF (2 mg) administered daily in approximately...treatment addressing this catabolic state. ThGRF, the only product currently under development...
- Theratechnologies: Phase II Clinical Study Completed in the United States -...
- Press release article from: PR Newswire November 28, 2002 700+ words
...Phase II study to evaluate the safety of ThGRF in diabetic patients has been completed...to be conducted in the United States on ThGRF. The Principal Investigator of the study...conducting in Canada, the US and Europe on ThGRF. We are quite pleased to have reached...
- Theratechnologies Reports Phase II Results for ThGRF in HIV associated...
- Press release article from: PR Newswire April 15, 2004 700+ words
...for its Phase II clinical trial, testing ThGRF in patients with HIV-associated lipodystrophy...and its clinical experts consider that ThGRF is well suited for Phase III testing as...of this study are important and suggest ThGRF as a potentially beneficial treatment for...
- Positive phase II results reported for ThGRF in HIV-associated lipodystrophy.
- Newspaper article from: Biotech Business Week May 10, 2004 700+ words
...for its phase II clinical trial, testing ThGRF in patients with HIV-associated lipodystrophy...and its clinical experts consider that ThGRF is well suited for phase III testing as...of this study are important and suggest ThGRF as a potentially beneficial treatment for...
Source: HighBeam Research, Study: ThGRF peptide improves immune function among elderly.(Brief...